Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.

User tries dermapen for hair loss and plans to use non-mainstream topicals like c60, ghk-cu, and ptd-dbm with valproic acid. They also use a head massager and modified LLLT belt for additional treatment.

A 27-year-old male with AGA and diffused thinning has been using oral Minoxidil, Finasteride, Vitamin D, B12, Iron, and Ketoconazole shampoo. Despite a hair transplant and improved blood levels, he continues to experience hair loss and suspects a possible misdiagnosis of Alopecia Areata Incognita.

The conversation discusses using pumpkin seed oil, saw palmetto, fo-ti, and astaxanthin for hair loss, with additional use of Nizoral shampoo. Users express skepticism about regrowth and suggest adding a micro derm roller or considering minoxidil and finasteride for better results.

The user experienced good hair growth results using a combination of finasteride, minoxidil, and a topical formulation, but faced temporary numbness as a side effect. They manage this by microdosing oral finasteride and minoxidil and using the topical formulation sparingly.

Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

A user was embarrassed by a pharmacist's loud mention of "minoxidil" for hair loss, sparking a discussion on the stigma and unprofessionalism. Users suggested online purchases or different pharmacies for privacy and reassured that most people don't notice others' purchases.

The conversation discusses using finasteride, dutasteride, minoxidil, cialis, and metformin to protect hair and health. Some users caution against self-prescribing these drugs due to potential risks and complications.

The user is using finasteride, HGH, GHK-CU, BPC-157, KPV, biotin/collagen/keratin vitamins, ketoconazole shampoo, and low-dose naltrexone to address hair loss, avoiding minoxidil due to past shedding experiences. Adenosine is discussed as a potential alternative to minoxidil, though it is noted to be expensive and hard to find.

Nutrafol, a hair loss supplement, has limited and potentially biased research, with one study showing a 10% increase in hair count for women after 6 months but no significant results for men. The user concludes that cheaper, well-studied options like minoxidil may be more effective, especially for men, given the lack of evidence supporting Nutrafol.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

A case study that suggests verteporfin may be able to help regrow donor hairs after FUE extraction, and the potential implications of this result. Treatments discussed include Minoxidil, Finasteride, and RU58841.

The conversation discusses skepticism about new hair loss treatments, with many users expressing doubt about the effectiveness and availability of future solutions. Current treatments like minoxidil, finasteride, and hair transplants are mentioned as reliable options.

The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.

The conversation is about the effectiveness of Anagain, Capixyl, Procapil, and Redensyl for hair loss, and whether anyone has experience using these ingredients, sometimes in combination with Minoxidil.

Topical formulations, natural products, and CAM therapies are being used to treat Androgenic alopecia to avoid side effects of Finasteride and Minoxidil. The review covers various low-risk, alternative treatment options.

Combining therapies like scyllo-inositol, alpha-ketoglutarate, and autophagy-inducing supplements may enhance hair growth and prevent hair loss. Reporting individual results can accelerate progress in hair loss treatments.

Finasteride is effective in promoting hair growth and reversing hair miniaturization in men with androgenetic alopecia, with improvements seen in various studies over different durations. Some users report initial side effects like ball ache, which often resolve as the body adjusts.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.

RU58841, Minoxidil, and finasteride are discussed as treatments for hair loss. RU58841 is highlighted for its potential effectiveness.

The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

Probiotics like L. reuteri ATCC PTA 6475 and B. longum BB536 may improve hair growth and density by reducing inflammation and reversing DHT damage. The user is trialing these probiotics personally, ordering them from the U.S. to Canada, and plans to continue if no adverse effects occur.

Topical sodium valproate may promote hair growth by inhibiting GSK3β, allowing beta-catenin to proliferate, but it has potential side effects and requires more research. The conversation also mentions skepticism about a product called Vdphlo1, which includes sodium valproate and other ingredients.

The conversation discusses using different concentrations of topical treatments for hair loss, specifically Minoxidil, Finasteride, Dutasteride, and Tretinoin. The user is considering higher concentrations after previous treatments were ineffective.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.